Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4–5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study
Journal of Thrombosis and Thrombolysis · 2023
DOI: 10.1007/s11239-023-02885-9 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Thrombosis and Thrombolysis, 2023. Verfasst von Yuan Lin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan. Hauptthemen laut MEDLINE: Atrial Fibrillation, Hemorrhagic Stroke, Kidney Failure, Chronic, Ischemic Stroke. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Chang Gung Memorial Hospital.
Abstract (Originalsprache)
The role of direct oral anticoagulants (DOAC) in patients with atrial fibrillation (AF) and stage 4-5 chronic kidney disease (CKD) is controversial. Electronic medical records from 2012 to 2021 were retrieved for patients with AF and stage 4-5 CKD receiving oral anticoagulants. Patients were separated into those receiving DOACs (dabigatran, rivaroxaban, apixaban, or edoxaban) or vitamin K antagonists (VKA). Primary outcomes included ischemic stroke (IS), systemic thrombosis (SE), major bleeding, gastrointestinal bleeding, hemorrhagic stroke, acute myocardial infarction, cardiovascular death, and all-cause death. Renal outcomes included eGFR declines, creatinine doubling, progression to dialysis, and major adverse kidney events (MAKE). The primary analysis was until the end of follow up and the results at 1-year and 2-year of follow ups were also assessed. 2,382 patients (DOAC = 1,047, VKA = 1,335) between 2012 and 2021 with AF and stage 4-5 CKD were identified. The mean follow-up period was 2.3 ± 2.1 years in DOCAs and 2.6 ± 2.3 years in VKA respectively. At the end of follow up, the DOAC patients had significantly decreased SE (subdistribution hazard ratio [SHR] = 0.50, 95% confidence interval [CI] = 0.34-0.73), composite of IS/SE (SHR = 0.78, 95% CI = 0.62-0.98), major bleeding (HR = 0.77, 95% CI = 0.66-0.90), hemorrhagic stroke (HR = 0.52, 95% CI = 0.36-0.76), and composite of bleeding events (SHR = 0.80, 95% CI = 0.69-0.92) compared with VKA patients. The IS efficacy outcome revealed neutral between DOAC and VKA patients (HR = 1.05, 95% CI = 0.79-1.39). In addition, DOAC patients had significantly decreased rates of eGFR decline > 50% (SHR = 0.75, 95% CI = 0.64-0.87), creatinine doubling (SHR = 0.80, 95% CI = 0.67-0.95), and MAKE (SHR = 0.81, 95% CI = 0.71-0.93). In patients with AF and stage 4-5 CKD, use of DOAC was associated with decreased rates of a composite of ischemic stroke/systemic embolism, a composite of bleeding events, and renal events compared to VKA. Efficacy and safety benefits associated with apixaban at standard doses were consistent throughout follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emergency Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
- Chang Gung University College of Medicine, Tao-Yuan, Taiwan.
- Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
- Institute of Clinical Medicine, Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Division of Cardiology, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan.
- Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
Förderung
- Chang Gung Memorial Hospital
Zitieren
APA
Lin, Y., Chao, T. F., Tsai, M. L., Tseng, C. J., Wang, T. H., Chang, C. H., Lin, Y. S., Yang, N. I., Chu, P. H., Hung, M. J., Wu, V. C., & Chen, T. H. (2023). Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4–5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-023-02885-9
Vancouver
Lin Y, Chao TF, Tsai ML, Tseng CJ, Wang TH, Chang CH, et al. Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4–5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study. Journal of Thrombosis and Thrombolysis. 2023. doi:10.1007/s11239-023-02885-9
BibTeX
@article{Lin2023,
author = {Lin, Yuan and Chao, Tze-Fan and Tsai, Ming-Lung and Tseng, Chin-Ju and Wang, Te-Hsiung and Chang, Chih-Hsiang and Lin, Yu-Sheng and Yang, Ning-I and Chu, Pao-Hsien and Hung, Ming-Jui and Wu, Victor Chien-Chia and Chen, Tien-Hsing},
title = {Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4–5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study},
journal = {Journal of Thrombosis and Thrombolysis},
year = {2023},
doi = {10.1007/s11239-023-02885-9}
}
EUVIMED